ApoB instead of LDL: the better marker for your heart risk?
Most people look only at their LDL level. Yet another marker often reflects your cardiovascular risk more accurately: ApoB. What's behind it and when it makes sense.
Cholesterol doesn't travel alone
Cholesterol is fat-soluble and can't float in watery blood. It's therefore packaged into transport particles called lipoproteins. Each of these particles carries exactly one molecule of apolipoprotein B as an address label — regardless of how much cholesterol is packed inside.
That's the key point. The LDL value measures the amount of cholesterol across all LDL particles combined. ApoB measures the number of particles. And what gets into the arterial wall isn't cholesterol as a substance, but the particle as a whole — it gets stuck there and triggers the inflammation that becomes plaque.
Why particle count is more accurate
Two people can have the same LDL cholesterol level and still carry very different risks. Someone with many small, cholesterol-poor particles needs more of them to reach the same measured value — and more particles mean more opportunities to get stuck in the arterial wall.
This pattern is common in insulin resistance, type 2 diabetes, abdominal obesity and high triglycerides. These are exactly the people for whom the LDL value most underestimates risk — and exactly the group where measuring ApoB provides the greatest added value.
What the data show
Marston and colleagues analysed data from several large studies in 2022. Their finding: ApoB predicted the risk of heart attack and other cardiovascular events better than LDL cholesterol or non-HDL cholesterol. When ApoB was included in the calculation, the other two values lost their independent predictive power.
Sniderman and colleagues reached the same conclusion in their 2019 review and added a practical advantage: ApoB can be measured in a standardised way, is not affected by fasting status and is not distorted by high triglycerides — unlike the calculated LDL.
Which values apply
As a rough guide, below 100 milligrams per decilitre is considered favourable for people without particular risk, below 80 for elevated risk, and below 65 for very high risk — such as after a heart attack or with familial hypercholesterolaemia. These thresholds correspond to the LDL targets set by European specialist societies.
Depending on the lab, testing costs twenty to forty francs and is not routinely offered everywhere. It is most useful when LDL and triglycerides don't match, in metabolic syndrome, with a family history, or when vascular changes are already known despite a normal LDL.
What the value can't tell you
ApoB is a risk marker, not a diagnosis. It says nothing about whether deposits are already present — for that you need imaging such as a calcium score or an ultrasound of the carotid arteries. And it doesn't replace the overall picture: blood pressure, smoking, blood sugar, physical activity and family history all still count.
What lowers this value is the same as what lowers LDL: less saturated fat, more fibre, weight loss where overweight is present, physical activity — and, when risk warrants it, statins or other medications. Treatment decisions belong in medical practice; this content does not replace medical advice.
How the YUTHI app helps you
You enter blood values with a date, and the app tracks ApoB, LDL, HDL and triglycerides as a combined trend. The side-by-side view is particularly revealing: when LDL drops but ApoB stays put, that tells you more than any single value on its own.
Vito and Vita explain what a value means rather than just colour-coding it. And they present the trend so you can show it at your next appointment — a two-year chart tells your doctor more than today's result alone.
That was the snapshot. The app turns it into daily support.
Measure every day instead of calculating once: Vito or Vita puts your numbers in context, builds you a weekly plan and speaks up when something stands out.
Launching at the end of 2026 — iPhone first, Android to follow. Let me know when it’s out ↓
Sources
- Marston NA, Giugliano RP, Melloni GEM, et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. JAMA Cardiol. 2022;7(3):250-256.
- Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287-1295.
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J. 2017;38(32):2459-2472.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188.